Cinobufagin

Cinobufagin has been shown to have clinical applications in cancer treatment. Cinobufagin can induce cell cycle arrest at the G2 and M phases as well as induce apoptosis in osteosarcoma cells. Potentially, cinobufagin could be used to stop proliferation of osteosarcoma cells as well as to induce apoptosis. At the protein level, cinobufagin treated osteoscarcoma cells showed an increase in the Bax and cleaved-PARP apoptotic proteins, while inhibiting the GSK-3ß/NF-?B signaling pathway. Literature citation: Yin JQ; Wen L; Wu LC; Gao ZH; Huang G; Wang J; Zou CY; Tan PX; Yong BC; Jia Q; Shen JN (2013). "The glycogen synthase kinase-3ß/nuclear factor-kappa B pathway is involved in cinobufagin-induced apoptosis in cultured osteosarcoma cells.". Toxicology Letters 218 (2): 129-36. doi:10.1016/j.toxlet.2012.11.006. PMID 23164673. Potential mode of action/Key words: Apoptosis inducer, Anticancer, Antitumoral